<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01914120</url>
  </required_header>
  <id_info>
    <org_study_id>QLQ-CN</org_study_id>
    <nct_id>NCT01914120</nct_id>
  </id_info>
  <brief_title>the Quality of Life Assessment of Lung Cancer Patients in China</brief_title>
  <official_title>A Multicenter, Observational, Phase III Clinical Study: the Quality of Life Assessment of Lung Cancer Patients in China.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is assess the quality of life of advanced non-small cell lung cancer
      (NSCLC) patients who are undergoing first-line chemotherapy, analyze the current status and
      tendency of quality of life (QOL). The method is to use the Functional Assessment of Cancer
      Therapy-Lung (FACT-L) scales, assess the quality of life before the chemotherapy, after 1st
      cycle of chemotherapy and after 2nd cycle. After 3 time-points, investigators analyze all the
      subscales and constructs of FACT-L. The assumption is the quality of life will be better
      after 2 cycle of chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Lung cancer is the most deadly cancer in the world, 85% lung cancer are non-small cell
           lung cancer (NSCLC). The quality of life of NSCLC patients become more and more
           important, because of most NSCLC is incurable.

        2. The recruitment will take place in 20 center all over the country and 500 patients will
           enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the change of quality of life</measure>
    <time_frame>Change from baseline quality of life at 6 weeks</time_frame>
    <description>use Functional Assessment of Cancer Therapy-Lung (FACT-L) scales assess the quality of life to all subjects.
before chemotherapy; after 1st chemotherapy; after 2nd chemotherapy;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Advanced non-small cell lung cancer patients diagnosed by pathological or cytological
        methods, and also have a imageological diagnosis within 6 weeks for clinical staging.

        Clinical stage IIIB or IV. Chemo-naive patients: have never receive any kind of anti-cancer
        chemotherapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age: &gt;18 and &lt;75 years old

          -  pathological or cytological diagnosis confirmed advanced non-small cell lung cancer

          -  Eastern Cooperative Oncology Group Performance Status: 0-2

          -  have never receive any kind of anti-cancer chemotherapy

          -  agree to regularly assessment of quality of life

          -  sign the informed consent form

        Exclusion Criteria:

          -  Currently attending any antitumor drug clinical trials

          -  Pregnancy or breast-feeding women

          -  Currently receiving anti-tumor chemotherapy, or received any antitumor chemotherapy
             previously.

          -  not suitable to participate in this test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YuXiang Ma</last_name>
    <phone>86-020-87343786</phone>
    <email>mayx@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <zip>510030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YuXiang Ma</last_name>
      <phone>8602087343786</phone>
      <email>mayx@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Li Zhang, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Shi Y, Xing P, Fan Y, Zhang X, Hu C, Wang C, Liu X, Chen X, Zhou J, Wang M, Wu M, Han B, Fan M. Current small cell lung cancer treatment in China. Thorac Cancer. 2015 May;6(3):233-8. doi: 10.1111/1759-7714.12218. Epub 2015 Jan 15. Review.</citation>
    <PMID>26273367</PMID>
  </reference>
  <reference>
    <citation>Zell JA, Ignatius Ou SH, Ziogas A, Anton-Culver H. Validation of the proposed International Association for the Study of Lung Cancer non-small cell lung cancer staging system revisions for advanced bronchioloalveolar carcinoma using data from the California Cancer Registry. J Thorac Oncol. 2007 Dec;2(12):1078-85.</citation>
    <PMID>18090578</PMID>
  </reference>
  <reference>
    <citation>Hopwood P, Stephens RJ. Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party. Br J Cancer. 1995 Mar;71(3):633-6.</citation>
    <PMID>7533520</PMID>
  </reference>
  <reference>
    <citation>Lutz S, Norrell R, Bertucio C, Kachnic L, Johnson C, Arthur D, Schwarz M, Palardy G. Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using the Lung Cancer Symptom Scale in a community hospital. J Palliat Med. 2001 Summer;4(2):157-65.</citation>
    <PMID>11441624</PMID>
  </reference>
  <reference>
    <citation>Vainio A, Auvinen A. Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group. J Pain Symptom Manage. 1996 Jul;12(1):3-10.</citation>
    <PMID>8718910</PMID>
  </reference>
  <reference>
    <citation>Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010 Aug 19;363(8):733-42. doi: 10.1056/NEJMoa1000678.</citation>
    <PMID>20818875</PMID>
  </reference>
  <reference>
    <citation>Splinter TA. Chemotherapy in advanced non-small cell lung cancer. Eur J Cancer. 1990;26(10):1093-9.</citation>
    <PMID>2177347</PMID>
  </reference>
  <reference>
    <citation>Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995 Jun;12(3):199-220.</citation>
    <PMID>7655830</PMID>
  </reference>
  <reference>
    <citation>Hollen PJ, Gralla RJ, Kris MG, Cox C. Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). Support Care Cancer. 1994 Jul;2(4):213-22. Review.</citation>
    <PMID>8087439</PMID>
  </reference>
  <reference>
    <citation>Cella D, Eton DT, Fairclough DL, Bonomi P, Heyes AE, Silberman C, Wolf MK, Johnson DH. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002 Mar;55(3):285-95.</citation>
    <PMID>11864800</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2013</study_first_submitted>
  <study_first_submitted_qc>July 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2013</study_first_posted>
  <last_update_submitted>August 26, 2015</last_update_submitted>
  <last_update_submitted_qc>August 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li Zhang</investigator_full_name>
    <investigator_title>Profressor</investigator_title>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>quality of life</keyword>
  <keyword>FACT-L</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

